AstraZeneca updates total voting rights count

AstraZeneca PLC reports its current voting share capital.

Rhea-AI Filing Summary

AstraZeneca PLC reports its current voting share capital. As at 28 February 2026, the company has 1,550,966,708 issued ordinary shares of US$0.25 each with voting rights, and no shares held in treasury. This means the total number of voting rights is 1,550,966,708.

Shareholders can use this total voting rights figure as the denominator when calculating whether they must notify the UK Financial Conduct Authority of holdings or changes in their interest under the Disclosure and Transparency Rules.

FAQ

What total voting rights did AstraZeneca (AZN) report as of 28 February 2026?

AstraZeneca reported a total of 1,550,966,708 voting rights as of 28 February 2026. This equals its issued ordinary share capital with voting rights, since no shares are held in treasury, so every issued share currently carries one vote.

How many AstraZeneca (AZN) shares are in issue and do they all have voting rights?

AstraZeneca has 1,550,966,708 issued ordinary shares of US$0.25 each with voting rights. The company holds no shares in treasury, so all issued ordinary shares currently carry voting rights and are included in the total voting rights figure.

Why is AstraZeneca’s (AZN) total voting rights figure important for shareholders?

The total voting rights figure of 1,550,966,708 is the denominator shareholders use to calculate their percentage interest. This helps determine whether they must notify the UK Financial Conduct Authority of holdings or changes under the Disclosure and Transparency Rules.

Did AstraZeneca (AZN) report any treasury shares in this 6-K filing?

AstraZeneca stated that no shares are held in Treasury. This means every issued ordinary share currently carries voting rights, and the number of issued ordinary shares equals the total voting rights reported in the notification.

What type of information does this AstraZeneca (AZN) Form 6-K provide?

This Form 6-K provides a voting rights and capital update under UK disclosure rules. It confirms the number of issued ordinary shares with voting rights, the absence of treasury shares, and the resulting total voting rights shareholders should use for regulatory reporting calculations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 12:00 PM Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Total Voting Rights

 2 March 2026

Transparency Directive

Voting rights and capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 28 February 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,550,966,708 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,966,708.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 02 March 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary